Title |
Human Apyrase to Disrupt Cancer Therapy
|
Institution |
APT THERAPEUTICS, INC., SAINT LOUIS, MO
|
Principal Investigator |
CHEN, RIDONG
|
NCI Program Director |
Andrew Kurtz
|
Cancer Activity |
Small Business - Cancer Treatment/ Therapy
|
Division |
SBIRDC
|
Funded Amount |
$196,745
|
Project Dates |
09/12/2008 - 09/11/2009
|
Fiscal Year |
2008
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
Hematology (100.0%)
Metastasis (100.0%)
|
Breast Cancer (100.0%)
|
Research Type |
Systemic Therapies - Discovery and Development
|
Abstract |
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics approach, we have successfully engineered an optimized human apyrase, APT102. With the Phase I grant support, we will determine whether APT102, alone or in combination with aspirin, is effective in inhibiting experimental spontaneous metastasis in mice. PUBLIC HEALTH RELEVANCE:Human apyrase represents a highly promising therapy for cancer treatment. We will determine whether the targeted apyrase, alone or in combination with aspirin, is effective in inhibiting experimental metastasis in mice. |